Open Targets
| Content | |
|---|---|
| Description | Public private partnership |
| Data types captured | Drug discovery |
| Organisms | Homo sapiens |
| Contact | |
| Primary citation | PMID 27899665 |
| Release date | 2014 |
| Access | |
| Website | Open Targets Consortium |
| Tools | |
| Web | Open Targets Platform |
Open Targets uses human genetics and genomics data for systematic drug target identification and prioritisation.
Background[edit]
The discovery and development of a new drug can take over a decade and is characterised by low success rates, where many of the therapeutic drugs that enter clinical trials never make it to the market. The failure in drug discovery often arises because the biological target chosen is not well enough understood.
Open Targets addresses this challenge by working in two areas, data integration and data generation, to assist early drug target decisions. Publicly available information relevant to targets and diseases is integrated in the Open Targets Platform, and high throughput experimental projects generate target-centred data in human, physiologically relevant systems to improve the strength of causal links between targets and diseases in three therapeutic areas, Immunology, Neurodegeneration and Oncology.[1].
Open Targets
Public-private partnership[edit]
The Open Targets Consortium was founded in 2014 by EMBL-EBI, GSK and Wellcome Sanger Institute and originally known as Centre for Therapeutic Target Validation [2] The partnership was joined by Biogen in 2016, Takeda in 2017, and Celgene in 2018, and is open to other partners in academia and/or industry. The goals of the partnership is to systematically find the best drug targets to safely and effectively treat disease; help others find good targets; and get those targets adopted into drug discovery pipelines.
Open Targets [3] is guided by pre‐competitive research and free exchange of ideas and expertise; it is committed to rapid publication and making data, methods and results publicly available.
Resources[edit]
Open Targets Platform[edit]
The Open Targets Platform is an integration system of public domain data that is used for free access to and visualisation of potential drug targets associated with diseases. It brings together multiple data sources [4] such as Genomics England PanelApp [5] and PheWAS catalog [6], which are combined in data types such as Genetic associations [7], scored and ranked to enable therapeutic target identification and prioritisation [8].
The Platform can be searched for targets associated with a disease such as asthma [9], or diseases associated with a target, such as ITGAL [10]. Up to 200 targets can be searched at once with the batch search [11] tool. The evidence and associations JSON files can be downloaded [12]. The Open Targets REST API [13] and Python client [14] are available for programmatic and customised access of the Open Targets Platform data.
See also[edit]
References[edit]
- ↑ "Science". www.opentargets.org.
- ↑ "Where do you start when developing a new medicine? - European Bioinformatics Institute". www.ebi.ac.uk.
- ↑ Open Targets (10 January 2018). "Open Targets" – via YouTube.
- ↑ "Data sources - Open Targets Platform Documentation". docs.targetvalidation.org.
- ↑ "Genomics England PanelApp". panelapp.genomicsengland.co.uk.
- ↑ "PheWAS - Phenome Wide Association Studies". phewascatalog.org.
- ↑ "Genetic associations - Open Targets Platform Documentation". docs.targetvalidation.org.
- ↑ Koscielny, Gautier; An, Peter; Carvalho-Silva, Denise; Cham, Jennifer A.; Fumis, Luca; Gasparyan, Rippa; Hasan, Samiul; Karamanis, Nikiforos; Maguire, Michael; Papa, Eliseo; Pierleoni, Andrea; Pignatelli, Miguel; Platt, Theo; Rowland, Francis; Wankar, Priyanka; Bento, A. Patrícia; Burdett, Tony; Fabregat, Antonio; Forbes, Simon; Gaulton, Anna; Gonzalez, Cristina Yenyxe; Hermjakob, Henning; Hersey, Anne; Jupe, Steven; Kafkas, Şenay; Keays, Maria; Leroy, Catherine; Lopez, Francisco-Javier; Magarinos, Maria Paula; Malone, James; McEntyre, Johanna; Munoz-Pomer Fuentes, Alfonso; O'Donovan, Claire; Papatheodorou, Irene; Parkinson, Helen; Palka, Barbara; Paschall, Justin; Petryszak, Robert; Pratanwanich, Naruemon; Sarntivijal, Sirarat; Saunders, Gary; Sidiropoulos, Konstantinos; Smith, Thomas; Sondka, Zbyslaw; Stegle, Oliver; Tang, Y. Amy; Turner, Edward; Vaughan, Brendan; Vrousgou, Olga; Watkins, Xavier; Martin, Maria-Jesus; Sanseau, Philippe; Vamathevan, Jessica; Birney, Ewan; Barrett, Jeffrey; Dunham, Ian (29 November 2016). "Open Targets: a platform for therapeutic target identification and validation". Nucleic Acids Research. 45 (D1): D985–D994. doi:10.1093/nar/gkw1055. PMID 27899665.
- ↑ "Open Targets Platform". www.targetvalidation.org.
- ↑ "Open Targets Platform". www.targetvalidation.org.
- ↑ "Open Targets Platform". www.targetvalidation.org.
- ↑ "Open Targets Platform". www.targetvalidation.org.
- ↑ "Open Targets API Documentation". api.opentargets.io.
- ↑ "opentargets - Python client for targetvalidation.org — opentargets 2.0.0 documentation". opentargets.readthedocs.io.
Soliciting a new page[edit]
This article "Open Targets" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Open Targets. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
